<DOC>
	<DOCNO>NCT01269047</DOCNO>
	<brief_summary>The main purpose study determine effect 16 week adjunctive pramlintide exenatide use glycemic control Type 1 Diabetes .</brief_summary>
	<brief_title>Use Exenatide Pramlintide Decrease Post-prandial Hyperglycemia</brief_title>
	<detailed_description>After sign informed consent , prior study enrollment , screen evaluation perform Clinical Research Center ( CRC ) . The evaluation consist : medical history , physical examination vital sign , Tanner staging , waist circumference . The following clinical laboratory test do : CBC , HbA1c , creatinine , Liver function test , amylase , adiponectin , leptin , C-reactive protein , lipid profile , IL-6 , lipase , urine pregnancy test ( appropriate ) microalbumin . A urine pregnancy test do study visit menstruate female . Also anti-GAD , ICA512 , anti-insulin antibody previously do record available . Each subject continuous glucose monitoring sensor ( CGMS ) insert need wear 3 day ( 72 hour ) . A person , train insert subcutaneous sensor , insert sensor . The sensor insert subcutaneously injector device . This site insertion similar insulin pump site insertion . A recorder attach sensor record blood glucose data 72 hour . The subject need test blood glucose least 4 time day wear sensor . The subject ask keep log diet , insulin exercise wear CGMS . At end 3 day sense period , subject remove sensor place recorder charger . The sensor bring back subject Visit # 1 . A Mixed Meal Tolerance Test perform visit ( describe ) : Preparation Mixed Meal Tolerance Test ( MMTT ) 1 . The test perform morning ( 7 10 AM ) 2 . Test conduct fast value capillary blood glucose meter 70-200 mg/dl ( 3.9-11.1 mMol ) . If blood glucose prior start MMTT great 350 mg/dl , urine ketone measure . If subject 's blood glucose le 70 mg/dl Mixed Meal Tolerance Test , receive 5-10 gram dextrose 50 % IV . If subject develop hyperglycemia MMTT ( expect ) , receive supplemental bolus fast act insulin base usual insulin sensitivity factor . The subject instruct study staff amount need . The subject administer bolus 3 . Participants injection withhold take long acting insulin morning test . Participants take short act insulin ( e.g . Humalog Novolog ) 2 hour test necessary withheld test . 4 . Participants insulin pump continue normal basal rate . Participants take short act insulin ( e.g . Humalog NovoLog ) 2 hour test necessary . 5 . The participant fasting least 8 hour food drink ( exception water ) . 6 . Local anesthetic may use need start I.V . line . Conducting Mixed Meal Tolerance Test ( MMTT ) 1 . Baseline blood sample draw -30 minute ; -10 minute 0 minute ( immediately participant start drink liquid meal ) Baseline sample include glucose , insulin , C-peptide , amylin , GLP-1 , glucagon active ghrelin . 2 . The participant standardized liquid meal : Boost HP 6 ml/kg , maximum 360 ml , ingest within 5 minute . 3 . Blood sample draw time : 15 , 30 , 60 , 90 120 minute glucose , insulin , C-peptide , amylin , GLP-1 , active ghrelin glucagon start ingestion Boost . 4 . After test complete , participant receive usual morning dose short act insulin analog . The short act analog dose accord subject 's usual sensitivity factor insulin carbohydrate ratio breakfast prescribe investigator . Subjects insulin pump therapy receive short act analog via pump dose accord subject 's usual sensitivity factor insulin carbohydrate ratio breakfast prescribe investigator . Subjects receive meal tray premeal insulin administer . A total 107.6 ml blood drawn screen visit . Visit 1 ( 0 month ) : If subject qualify screen , opportunity enroll study . They meet study coordinator CRC make adjustment insulin dosage ( necessary ) optimize treatment improve glycemic control . As show preliminary data section , insulin glargine ( Lantus ) , long act analog , may use mix short act insulin analog decrease total number injection . This may also increase compliance medication regimen . Parental supervision medication administration advise . Hypoglycemic event adherence insulin regimen note . QOL questionnaires administered.Subjects vital sign , waist circumference , HbA1C , Glycomark , urine pregnancy test ( appropriate ) .Dual-emission X-ray absorptiometry ( DEXA ) body scan do day estimate total body fat . Patients also ask bring food diary keep 3 day analyze calorie consume . During entire study period , subject assess use home blood glucose monitor electronically transfer data PI ( Glucomon ) . Data review daily week 1 2 , week week 3 4 . Starting week 5 , data review every two week remainder study . Contact similar subject . Subjects receive Glucomon visit . At visit , subject randomize one three possible group . Randomization : Subjects randomize use random number table . Group 1 : Pramlintide + Insulin Group 2 : Exenatide + Insulin Group 3 : Insulin monotherapy Study Medications : Exenatide dosing : Exenatide start 1.25 mcg previously determine u early study . Exenatide injection give subcutaneously twice day ( within 30 minute start meal ) separate insulin injection . Exenatide dose titrate 2.5 5 mcg ( depend response ) keep 2 hr post-prandial blood glucose concentration 200 mg/dl . Initially , premeal bolus insulin dose reduce 30 % . Basal insulin dose change . Insulin dose may increase pre-meal blood glucose concentration great 150 mg/dl decrease post-prandial hyperglycemia . Pramlintide dosing : Based preliminary study , pramlintide start 15 mcg titrate 30-45 mcg cap 60 mcg . This base demonstration acceptable post-prandial glucose excursion without hypoglycemia . Subjects receive pramlintide subcutaneously twice day ( within 30 minute start meal ) separate insulin injection . Initially , premeal bolus insulin dose reduce 30 % .Insulin dose may increase pre-meal blood glucose concentration great 150 mg/dl decrease post-prandial hyperglycemia . At outset , decrease premeal bolus insulin dose 30 % group , insulin may increase necessary subject well able tolerate drug ( personal communication regard unpublished data Dr. David Maggs , Amylin pharmaceutical , management exenatide and/or pramlintide insulin ) . Insulin monotherapy : Subjects randomize insulin monotherapy continue either long-acting short act insulin analog subcutaneous insulin pump therapy . Insulin dose change make optimize therapy . A total 5.5 ml blood drawn Visit 1 . Visit 2 ( 1 month ) : Subjects vital sign , waist circumference , HbA1C , Glycomark , urine pregnancy test ( appropriate ) . Adherence insulin/medication regimen adverse event reporting obtain . A total 5.5 ml blood drawn Visit 2 . Visit 3 ( 4 month ) : Subjects undergo medical history , physical examination , vital sign , waist circumference , HbA1C , Glycomark , amylase , lipase , Liver function test , CBC , creatinine , adiponectin , leptin , C-reactive protein , lipid profile , IL-6 , urine pregnancy test ( appropriate ) . Adherence insulin/medication regimen adverse event reporting obtain . Quality Life ( QOL ) questionnaires repeat . Additionally , subject come fast undergo MMTT describe Screening visit subject pramlintide/ exenatide ( Byetta ) receive dose prior boost administration . DEXA scan do day estimate total body fat . Patients also ask bring food diary keep 3 day analyze calorie consume . Each subject continuous glucose monitoring sensor ( CGMS ) insert need wear 3 day ( 72 hour ) . A person , train insert subcutaneous sensor , insert sensor . The subject receive instruction completion logsheets properly remove sensor . Pramlintide exenatide stop subject remove sensor 3 day insertion . Each family would give prepay envelope mail back sensor recorder remain study medication . A total 104.6 ml blood drawn Visit 3 . Control subject MMTT receive pramlintide exenatide one time dose without insulin . Visit 4 ( 6-7 month ) : This post-study visit . Subjects undergo medical history , physical examination , vital sign , waist circumference . This visit similar visit 3 test lab work pregnancy test ( appropriate ) . Except subject DEXA scan Continuos Glucose Monitoring Sensor . If subject receive pramlintide previously study drug visit 3 receive exenatide one time dose MMTT . QOL questionnaires repeat . Adherence insulin regimen adverse event reporting obtain . Subjects return Glucomon blood glucose log book visit . A total 104.6 ml blood drawn Visit 4 . During entire study period , subject assess use data collect study issue home blood glucose monitor . The subject 's blood glucose data electronically transmit PI ensure data security patient privacy . Data review daily week 1 2 , week week 3 4 . Starting week 5 , data review every two week remainder study .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Pramlintide</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Islet Amyloid Polypeptide</mesh_term>
	<criteria>1 . Age 12 21 year . 2 . HbA1C le 9 % 3 . Subjects must intensive insulin management 4 . Tanner stage great equal 3 5 . Having Type 1 Diabetes least one year 6 . Type 1Diabetes define ADA criterion least one follow antibody a. AntiGAD ( glutamic acid decarboxylase ) b. Antiislet cell 512 ( ICA512 ) c. Antiinsulin 7 . Willing give consent . 1 . Type 2 diabetes . 2 . Having chronic condition except hypothyroidism stable medication . 3 . On chronic medication may affect glucose excursion . 4 . Anemia define Hb le 9 gm/dl . 5 . Abnormal amylase , lipase creatinine ( twice normal ) . 6 . Abnormal Liver function test ( three time normal ) 7 . Unsupportive family environment determine clinician and/or social worker . 8 . Pregnant lactating mother</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>type 1 diabetes</keyword>
	<keyword>Symlin</keyword>
	<keyword>Byetta</keyword>
	<keyword>CGMS iPro</keyword>
</DOC>